ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Quinolones >Pazufloxacin

Pazufloxacin

Pazufloxacin Structure
CAS No.
127045-41-4
Chemical Name:
Pazufloxacin
Synonyms
T-3761;ALKALYL;PAZUFLOXAXIN;Pazufloxacin;Pazufloxacine;PAZUFLOXACIN 98+%;Pazufloxacin318.3;PAZUFLOXACIN(ALKALYL);Pazufloxaxin mesilate;Pazufloxacinmyesylate
CBNumber:
CB2423188
Molecular Formula:
C16H15FN2O4
Molecular Weight:
318.3
MOL File:
127045-41-4.mol
MSDS File:
SDS
Modify Date:
2023/5/18 11:31:07

Pazufloxacin Properties

Melting point 269-271°C
alpha D25 -88.0° (c = 0.5 in 0.05N aq NaOH)
Boiling point 531.5±50.0 °C(Predicted)
Density 1.56
storage temp. 2-8°C
solubility Aqueous Base (Slightly, Sonicated), DMSO (Slightly, Heated), Methanol (Slightly)
pka 5.05±0.40(Predicted)
color Off-White to Pale Yellow
CAS DataBase Reference 127045-41-4(CAS DataBase Reference)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302+H312+H332
Precautionary statements  P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312
Hazard Codes  Xn,C,F
Risk Statements  20/21/22-34-11
Safety Statements  36/37-45-36/37/39-26-16
WGK Germany  3
RTECS  UU8815300
Toxicity LD50 i.v. in male mice: >500 mg/kg (Todo)

Pazufloxacin price More Price(1)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich(India) 34213 Pazufloxacin VETRANAL?, analytical standard 127045-41-4 25MG ₹15717.9 2022-06-14 Buy
Product number Packaging Price Buy
34213 25MG ₹15717.9 Buy

Pazufloxacin Chemical Properties,Uses,Production

Description

Pazufloxacin is a novel quinolone marketed for the treatment of bacterial infections in Japan. This tricyclic fluoro-quinolone can be synthesized in 11 steps from commercially available 2,3,4,5tetrafluorobenzoic acid. The cyclopropyl substituent is first introduced in 6 steps including 4-F-substitution with tert-butylcyanoacetate, decarboxylation, aa alkylation with 1 ,Zdibromoethane, partial nitrile hydrolysis and Hoffmann-rearrangement. The pyridoxazine ring is then introduced in 5 steps including 6-ketoester formation and pryridoxazine annulation. Pazufloxacin displays a broad spectrum activity against Grampositive and Gram-negative bacteria, although it is less active that ciprofloxacin against pneumococci and is not active against ciprofloxacin-resistant isolates. In patients with gonococcal urethritis a high prevalence of fluoroquinolone-resistant N. gonorrhoeae isolates with the Ser-91-to-Phe mutation in GyrA was observed. However, good clinical responses have been seen in clinical trials of patients with urinary tract infections and to a lesser extent with respiratory tract infections. Pazufloxacin is mainly excreted in urine with a short half-life (2-2.5 h). It has a phototoxicity equal to that of ciprofloxacin and its adverse effect profile resembles that of other quinolones.

Uses

Pazufloxacin is a potential antimicrobial and/or antiviral agent.

Pharmaceutical Applications

A tricyclic fluoroquinolone, formulated as mesylate and hydrochloride salts for oral or parenteral use or as a methane sulfonate (eye ointment).
It displays good activity in vitro against methicillin susceptible Staph. aureus (MIC 0.2 mg/L), but is inactive against Str. pyogenes, Str. pneumoniae (MIC ≥4 mg/L) and enterococci. L. pneumophila is inhibited by 0.03 mg/L. Activity against Enterobacteriaceae, fastidious Gram-negative bacilli, Ps. aeruginosa and Acinetobacter spp. is similar to that of ofloxacin. It is weakly active against Sten. maltophilia and Burkholderia cepacia (MIC c. 2 mg/L). Against M. tuberculosis, MICs range from 0.8 to 4 mg/L. It is inactive against anaerobes.
After oral doses of 100 or 400 mg, peak plasma concentrations range from 0.94 mg/L (100 mg) to 4.5 mg/L (400 mg) after <1 h. The apparent elimination half-life is around 2 h. Most of the administered dose is eliminated in urine, about 70% within 24 h. Four metabolites have been reported. In elderly patients, according to the renal function, the peak plasma concentration may be elevated (up to 5.6 mg/L) and significantly delayed (2–6 h). The plasma protein binding ranges from 17% to 28%.

Global( 183)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Uni Trade Agencies 08068442234Ext 578 Mumbai, India 10 58 Inquiry
Henan Tianfu Chemical Co.,Ltd. +86-0371-55170693 +86-19937530512 China 21662 55 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29899 58 Inquiry
Chongqing Chemdad Co., Ltd +86-023-6139-8061 +86-86-13650506873 China 39916 58 Inquiry
CONIER CHEM AND PHARMA LIMITED +8618523575427 China 49403 58 Inquiry
SIMAGCHEM CORP +86-13806087780 China 17367 58 Inquiry
Dideu Industries Group Limited +86-29-89586680 +86-15129568250 China 23430 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15372 58 Inquiry
Baoji Guokang Bio-Technology Co., Ltd. 0917-3909592 13892490616 China 9316 58 Inquiry
PAZUFLOXAXIN T-3761 (s)-yclopropyl)-9-fluoro-3-methyl-7-oxo Pazufloxacinmyesylate (3S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-2,3-DIHYDRO-3-METHYL-7-OXO-7H-PYRIDO[1,2,3-DE]-1,4-BENZOXAZINE-6-CARBOXYLIC ACID ALKALYL Pazufloxaxin mesilate PAZUFLOXACIN 98+% (S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid PAZUFLOXACIN (PREPARATION FOR PAZUFLOXACIN MESILATE) PAZUFLOXACIN(ALKALYL) 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo- (9CI) (-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)- (9CI) 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- (S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-3-METHYL-7-OXO-3,7-DIHYDRO-2H-[1,4]OXAZINO[2,3,4-IJ]QUINOLINE-6-CARBOXYLIC ACID 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9- fluoro-3-methyl-7-oxo-, (S)- Pazufloxacin318.3 Pazufloxacine Pazufloxacin (S)-10-(1-aMinocyclopropyl)-9-fluoro-3-Methy... (S)-10-(1-Aminocyclopropyl)-9-Fluoro-2,3-Dihydro-3-Methyl-7-Oxo-7H-Pyrido(1,2,3-De)-1,4-Benzoxazine-6-Carboxylic Acid 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)- Pazufloxacin USP/EP/BP CAS No.127045-41-4 Pazufloxacin 127045-41-4 C37H63NO9 C16H15FN2O4 BacteriostaticAntibiotics ChinolonesAlphabetic PA - PENAnalytical Standards Pharmacology Standards Antibiotics Chemical Structure Chromatography P Principle API's